Approved indications: Zurzuvae is FDA-approved for the treatment of postpartum depression (PPD) in adults; it was studied in women whose depressive episode began in the third trimester of pregnancy or within about 4 weeks after delivery and is used as a single 14-day course.

Off-label uses: Zuranolone has been studied for major depressive disorder and other mood conditions, so some clinicians may consider off-label use in severe depressive episodes outside the postpartum period, but these uses are not FDA-approved and the evidence is less robust than for PPD, so access and insurance coverage may be limited.

Efficacy and onset: In clinical trials for PPD, many patients showed meaningful improvement in depression scores by about Day 3, with clear benefit by Day 15 (end of the 14-day course) and symptom reductions that often persisted for at least 4 weeks after the last dose.

Comparison to other treatments: Unlike standard antidepressants that are taken daily for months and may take several weeks to work, Zurzuvae is a once-daily, 14-day regimen with faster onset, but long-term durability of benefit, the need for maintenance therapy or retreatment, and its exact place in therapy compared with other antidepressants and IV brexanolone are still being clarified.

Typical adult dosing for postpartum depression: The usual regimen is 50 mg by mouth once each evening for 14 days, taken with a fat-containing meal (about 400–1,000 calories with 25–50% of calories from fat) to ensure the medicine is absorbed properly.

How to take it: Swallow the capsules whole with liquid at about the same time each evening, without crushing or chewing them, and plan not to drive or do other hazardous activities for at least 12 hours after each dose.

Dose adjustments: Your clinician may lower the dose to 40 mg once daily if you have troublesome sleepiness or other CNS-depressant effects, and to 30 mg once daily if you have severe liver impairment, moderate to severe kidney impairment, or you must take a strong CYP3A4 inhibitor.

Course length and repeats: Zurzuvae is intended as a single 14-day course; its safety and effectiveness beyond one course or for repeated courses in the same pregnancy-related episode have not been firmly established.

Missed doses: If you miss an evening dose, skip it and take your next dose at the usual time the following evening; do not take extra capsules on the same day to make up for a missed dose, but continue until you have completed the prescribed 14 doses.

Overdose: If you take more than prescribed or combine Zurzuvae with large amounts of alcohol or other sedating medicines, seek emergency care or contact Poison Control right away, as overdose may cause profound drowsiness, confusion, breathing problems, or loss of consciousness.

Common side effects: The most frequent side effects are sleepiness or drowsiness, dizziness, diarrhea, fatigue or low energy, common cold symptoms (nasopharyngitis), and urinary tract infections; these usually begin during the 14-day course, are often mild to moderate, but drowsiness and dizziness can be pronounced for some people.

Serious or rare adverse effects: Seek immediate medical attention for severe confusion, extreme sleepiness or unresponsiveness, trouble breathing, falls or injuries related to sedation, new or worsening thoughts of self-harm, or signs of a serious allergic reaction such as swelling of the face or throat, difficulty swallowing or breathing, or a severe rash.

Warnings and precautions: Zurzuvae carries a boxed warning for impaired ability to drive or do hazardous activities; patients must avoid driving, operating machinery, or similar tasks for at least 12 hours after each dose, and may not recognize how impaired they are.

Pregnancy and breastfeeding: Animal data suggest a risk of fetal harm, so Zurzuvae is generally avoided in pregnancy, and people who can become pregnant should use effective contraception during treatment and for 1 week after the last dose; the drug passes into breast milk at low levels, so breastfeeding decisions should balance the benefits of treatment and breastfeeding against the unknown risks to the infant, often with close monitoring or temporary pumping and discarding of milk.

Age limits and organ disease: Safety and effectiveness are established only for adults; it is not recommended for children, and dose reductions are used in people with severe liver disease or moderate to severe kidney impairment.

Abuse and dependence: Zurzuvae is a Schedule IV controlled substance and can cause CNS-depressant effects and physical dependence, so it should be used cautiously in people with a history of substance use disorders.

Relative safety versus other drugs: Compared with many traditional antidepressants, Zurzuvae is taken for a shorter period but has stronger short-term sedation and driving restrictions; unlike IV brexanolone, however, it can be taken at home without continuous monitoring.

Side-effect reporting and safety updates: Patients should promptly tell their prescriber about any concerning reactions, and side effects can be reported directly to the FDA through the MedWatch program or to the manufacturer, where ongoing safety communications and labeling updates are posted.

Other prescription and OTC medicines: Drugs that depress the central nervous system—such as benzodiazepines, opioids, sleep aids, certain antihistamines, and some antidepressants—can add to Zurzuvae’s drowsiness and confusion, so combined use should be limited, closely monitored, or may require a lower Zurzuvae dose.

Alcohol, cannabis, and recreational substances: Drinking alcohol or using other sedating substances (including some cannabis products) during the 14-day course can significantly increase the risk of dangerous sedation, falls, and breathing problems, and is generally advised against.

Metabolism and enzyme interactions: Strong CYP3A4 inducers (for example, rifampin, carbamazepine, phenytoin, or St. John’s wort) can reduce Zurzuvae levels and effectiveness and should usually be avoided, while strong CYP3A4 inhibitors (such as some azole antifungals, macrolide antibiotics, and HIV protease inhibitors) raise levels and require a reduced 30-mg daily dose.

Food and diagnostic procedures: Zurzuvae should be taken with a fat-containing meal to work properly; there are no specific known interactions with imaging contrast agents or routine diagnostic procedures, but sedation may affect your ability to safely undergo or travel to and from appointments.

Conditions needing extra caution: Careful assessment is needed in people with severe liver disease, moderate to severe kidney impairment, a history of substance use disorder, high fall risk, other serious psychiatric illnesses, or those who are pregnant or planning pregnancy, and it is not established for children.

Monitoring: Before and during treatment, clinicians typically review all medicines and supplements, check kidney and liver function when appropriate, and monitor for excessive sedation, changes in mood or behavior, or suicidal thoughts; routine ECGs or frequent blood tests are not usually required unless other health conditions indicate a need.

Q: What is Zurzuvae prescribed for?
A: Zurzuvae is an oral, once-daily, 14-day treatment approved for postpartum depression in adults.

Q: How quickly might I start to feel better on Zurzuvae?
A: In clinical studies, some people noticed improvement in depression symptoms within about 3 days, with full benefit typically assessed at Day 15 and effects that often lasted several weeks after finishing the course.

Q: Can I breastfeed while taking Zurzuvae?
A: Zurzuvae passes into breast milk at low levels, so you and your clinician should weigh the benefits of breastfeeding and treatment against the unknown risks to your baby and decide together whether to continue breastfeeding, temporarily pump and discard milk, or pause breastfeeding during and shortly after the 14-day course.

Q: Is it safe to drive while I am taking Zurzuvae?
A: No—because of the risk of significant drowsiness and slowed reactions, you should not drive or do other potentially dangerous activities for at least 12 hours after each dose throughout the 14 days of treatment.

Q: Can I take Zurzuvae with my current antidepressant?
A: Zurzuvae can be used alone or in addition to another oral antidepressant, but your prescriber must review all your medicines to adjust doses and monitor for added side effects such as extra sleepiness or dizziness.

Q: Is Zurzuvae addictive?
A: Zurzuvae is a Schedule IV controlled substance with some potential for misuse and physical dependence, so it should be taken exactly as prescribed and stored securely, especially if anyone else in the household has a history of substance use problems.

Storage: Store Zurzuvae capsules at room temperature, about 68°F to 77°F (20°C to 25°C), in the original container with the cap tightly closed, away from excess heat, moisture, and light, and always out of reach of children and pets.

Disposal: After you complete the 14-day course or if capsules become expired or are no longer needed, take unused medicine to a drug take-back program or follow your pharmacist’s or local waste authority’s instructions for household medicine disposal; do not flush capsules down the toilet or pour them down the sink unless specifically instructed to do so.